AstraZeneca and Heptares to develop novel immuno-oncology treatments
6 August 2015 | By Victoria White
AstraZeneca and Heptares Therapeutics have entered into a licensing agreement to develop A2A receptor-blocking compounds as cancer immunotherapies...